PD-1 Resistant Head and Neck Cancer (HNC) Market Landscape Report 2021
August 31, 2021 04:08 ET
|
Research and Markets
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology and Market Forecast 2030" report has been added to ResearchAndMarkets.com's...
F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA
August 04, 2021 08:00 ET
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
Global $15.1 Bn Immuno-oncology Clinical Trials Market to 2028
July 30, 2021 07:23 ET
|
Research and Markets
Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The "Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Design...
Global Oncology Based In-Vivo CRO Markets, 2021-2027: Focus on Solid Tumors, Blood Cancer, Other Indications
July 27, 2021 08:08 ET
|
Research and Markets
Dublin, July 27, 2021 (GLOBE NEWSWIRE) -- The "Oncology Based In-Vivo CRO - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Oncology...
F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors
July 26, 2021 08:00 ET
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company...
Cybrexa Therapeutics Expands Scientific Advisory Board With Appointment of Leader in Lung Cancer Research Roy Herbst, M.D., Ph.D.
August 03, 2020 07:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics Completes Successful Pre-IND Meeting With FDA for CBX-12 (alphalex™-exatecan), a Novel Treatment for Solid Tumors
July 07, 2020 07:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., July 07, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics Announces CBX-12 as Lead Development Program
January 09, 2020 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer
November 04, 2019 01:30 ET
|
Erytech Pharma S.A.
Trial opened for patient enrollment in the United States Independent Data Monitoring Committee recommends continuation of the trial as planned LYON, France and CAMBRIDGE, Mass., Nov. 04, 2019 ...
Admera Health Expands Liquid Biopsy Offering to Include Detection of Copy Number Variation and Microsatellite Instability
October 23, 2018 09:13 ET
|
Admera Health, LLC
SOUTH PLAINFIELD, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- At CAP18, in Chicago, IL, Admera Health (www.admerahealth.com), unveiled an expansion to its next generation sequencing (NGS) based...